A multilaboratory, multicountry study to determine MIC quality control ranges for phenotypic drug susceptibility testing of selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid

Journal of Clinical Microbiology

Volumn 54, Issue 12, 2016, Pages 2963-2968

  Kaniga, Koné ^a   Cirillo, Daniela M ^b   Hoffner, Sven ^c   Ismail, Nazir A ^d,e   Kaur, Devinder ^f   Lounis, Nacer ^g   Metchock, Beverly ^h   Pfyffer, Gaby E ⁱ   Venter, Amour ^j  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e UNIVERSITY OF PRETORIA   (South Africa)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ LUZERNER KANTONSSPITAL   (Switzerland)

^j STELLENBOSCH UNIVERSITY   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NICOTINAMIDE; OFLOXACIN; PROTIONAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; BROTH DILUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; STANDARDIZATION; CLINICAL TRIAL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PROCEDURES; QUALITY CONTROL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; FLUOROQUINOLONES; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUALITY CONTROL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84997611192     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01138-16     Document Type: Article

References (21)

1. WHO. 2015. Global tuberculosis report 2015. WHO, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059 -eng.pdf?ua-1.
2. WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO, Geneva, Switzerland. http:// apps.who.int/iris/bitstream/10665/70500/1/WHO-HTM-TB-2008.392 -eng.pdf?ua-1&ua-1.
3. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
4. U.S. Department of Health and Human Services, Food and Drug Administration. 2009. Guidance for industry: Microbiological data for systematic antibacterial drug products- development, analysis, and presentation. U.S. FDA, Washington, DC. http://www.fda.gov/downloads /drugs/guidancecomplianceregulatoryinformation/guidances/ucm182288 .pdf.
5. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: Antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693-698. http://dx .doi.org/10.2471/BLT.11.096644.
6. Pasipanodya J, Srivastava S, Gumbo T. 2012. New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 56:5428. http://dx .doi.org/10.1128/AAC.00976-12.
7. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, Weiner M, McIlleron H, Kirkpatrick CM. 2012. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 56:3857-3863. http://dx.doi.org/10 .1128/AAC.00048-12.
8. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A. 2016. A multilaboratory, multicountry study to determine bedaquiline MIC quality control ranges for phenotypic drug-susceptibility testing. J Clin Microbiol 54:2956-2962. http://dx .doi.org/10.1128/JCM.01123-16.
10. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Martin A, Takiff H, Vandamme P, Swings J, Palomino JC, Portaels F. 2006.Anew rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 58:327-331. http://dx.doi.org/10.1093/jac/dkl231.
12. Peñuelas-Urquides K, Villarreal-Treviño L, Silva-Ramírez B, Rivadeneyra-Espinoza L, Said-Fernández S, de León MB. 2013. Measuring of Mycobacterium tuberculosis growth. A correlation of the optical measurements with colony forming units. Braz J Microbiol 44:287-289.
13. Coban AY, Birinci A, Ekinci B, Durupinar B. 2004. Drug susceptibility testing of Mycobacterium tuberculosis by the broth microdilution method with 7H9 broth. Mem Inst Oswaldo Cruz 99:111-113. http://dx.doi.org/10.1590/S0074-02762004000100020.
14. Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. 2010. Wild-typeMICdistributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 65:946-952. http://dx.doi.org/10.1093/jac/dkq091.
15. Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T. 2010. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 48:1853-1858. http://dx.doi.org/10.1128/JCM.00240-10.
16. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA. 2009. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 64:786-793. http: //dx.doi.org/10.1093/jac/dkp262.
17. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10 .1128/CMR.00047-06.
18. Pascual A, Garcia I, Ballesta S, Perea EJ. 1999. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 43:12-15.
19. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke BF. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 50:841-851. http://dx.doi .org/10.1128/AAC.50.3.841-851.2006.
20. Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. 2010. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 54:2534- 2539. http://dx.doi.org/10.1128/AAC.01761-09.
21. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. 2010. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 54:1728-1733. http://dx.doi.org/10.1128/AAC.01355-09.